Claudio Calonder results 2
· Newest (Page 1/1, per page 25)
Author: Claudio Calonder ×Clear All Filters
Search Results
The determination of a tailored anti-drug antibody (ADA) testing strategy is based on the immunogenicity risk assessment to allow a correlation of ADAs with changes to pharmacokinetics, efficacy, and safety. The clinical impact of ADA formation refines the immunogenicity risk assessment and defines appropriate risk mitigation strategies. Health agencies request for high-risk biotherapeutics to extend ADA monitoring for patient...
Previous1Next